Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 14/20 | 0.53 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742580 | 0.86 | PTPN1 (0.49) | PTPN1PTPN22 | |
| SCHEMBL3737900 | 0.78 | PTPN1 (0.47) | PTPN1PTPN22CNR1CNR2 | |
| SCHEMBL6503209 | 0.78 | PTPN1 (0.68) | PTPN1PTPN22CNR1CNR2 | |
| SCHEMBL3737906 | 0.77 | PTPN1 (0.45) | PTPN1PTPN22 | |
| SCHEMBL3742594 | 0.76 | PTPN1 (0.47) | PTPN1PTPN22 | |
| SCHEMBL5987362 | 0.73 | PTPN1 (0.47) | PTPN1PTPN22 | |
| SCHEMBL2892290 | 0.71 | PTPN1 (0.61) | PTPN1PTPN22 | |
| SCHEMBL3740606 | 0.71 | PTPN1 (0.54) | PTPN1PTPN22 | |
| SCHEMBL3740609 | 0.71 | PTPN1 (0.54) | PTPN1PTPN22 | |
| SCHEMBL6533772 | 0.70 | PTPN1 (1.00) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PPM1B, PTPN1, PTPN5 | PTPN1 2/4885PTPN22 8/4885ADRB2 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.